重组人血管内皮抑制素联合化疗治疗多种晚期恶性肿瘤的临床观察  

The Clinical Observation of Rh-Endostatin Injection Combined with Chemotherapy for the Advanced Malignancies

作　　者：聂学诚[1] 种道群[1] 邱泗安 袁蕾蕾[1] 孔令东 康宝金 汤良[1] 张宾[1] 李瑞[1] 

机构地区：[1]济宁市第一人民医院肿瘤科,山东济宁272111 [2]兖州市中医院,山东兖州272100 [3]兖矿集团总医院,山东邹城273500 [4]兖州市人民医院,山东兖州272100

出　　处：《肿瘤基础与临床》2010年第3期220-222,共3页journal of basic and clinical oncology

摘　　要：目的观察重组人血管内皮抑制素（恩度）联合化疗治疗晚期恶性肿瘤的有效性和安全性。方法 84例经病理组织学或细胞学检查确诊的Ⅲ~Ⅳ期恶性肿瘤患者,其中非小细胞肺癌（NSCLC）41例,骨软组织肉瘤12例,其他31例。均接受恩度联合化疗,恩度15 mg静脉滴注,d1-14,第5天开始联合化疗,恩度共使用14 d,化疗21 d为1周期。按照RECIST标准评价近期疗效,参照Karnofsky评分变化评价生活质量（QOL）,按照NCICTC标准评价毒副反应。至少2周期后评价疗效和毒副反应。结果全组84例中,有81例可以评价客观疗效,84例均可进行安全性评价。81例可评价患者中,PR 23例,SD 43例,PD 15例,RR及DCR分别为28.4%、81.5%;治疗后有8例QOL改善,38例稳定,即QOL的改善稳定率达到56.8%。Ⅲ-Ⅳ度毒副反应发生率低,其中白细胞减少2例,血小板减少1例,恶心、呕吐1例,疲乏1例。结论恩度联合化疗可以改善晚期恶性肿瘤患者的生活质量,与化疗药物联合应用具有一定的协同作用;恩度毒副反应低,安全性好。Objective To investigate the efficacy and safety of rh-endostatin（endostar） combined with chemotherapy for the advanced malignancies.Methods Endostar combined with chemotherapy was administrated for 84 malignant cases of stage Ⅲ-Ⅳ（including 41 cases of non-small cell lung cancer（NSCLC）,12 cases of osteosarcoma and soft-tissue sarcomas,31 cases of other cancers） confirmed by histopathology or cytopathology.Endostar and chemotherapy were given.The efficacy was evaluated strictly after 2 cycles according to RECIST criteria,and the quality of life（QOL） was evaluated according to Karnofsky scores.The safety was evaluated after 2 cycle according to NCICTC criteria.Results 81 cases were evaluated for the efficacy among the 84 cases that were capable of safety evaluation.Among the 81 evaluable cases,there were 23 cases achieved PR,43 cases SD,and 15 cases PD.RR was 28.4%,and DCR was 81.5%.QOL was improved for 8 cases,stabled 38 cases. The occurrence rates of Ⅲ-Ⅳ grade toxicities were low,including neutropenia 2 cases,thrombocytopenia 1 case,nausea and vomiting 1 case,lassitude 1 case.Conclusion The QOL of patients with advanced malignancies may be improved by endostar combined with chemotherapy,and they have the synergetic effects of endostar.The toxicities are tolerated.

关 键 词：晚期恶性肿瘤 重组人血管内皮抑制素 化疗 

分 类 号：R730.53[医药卫生—肿瘤]